BeiGene
BGNE
#934
Rank
S$28.26 B
Marketcap
$254.06
Share price
-2.10%
Change (1 day)
-4.25%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -S$1.19 Billion

According to BeiGene 's latest financial reports the company's current earnings are S$3.09 Billion. In 2023 the company made an earning of -S$1.63 Billion, an increase over its 2022 earnings that were of -S$2.41 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -S$1.19 Billion-26.74%
2023 -S$1.63 Billion-32.52%
2022 -S$2.41 Billion24.39%
2021 -S$1.94 Billion-13.21%
2020 -S$2.23 Billion72.69%
2019 -S$1.29 Billion36.01%
2018 -S$0.95 Billion616.83%
2017 -S$0.14 Billion-15.24%
2016 -S$0.16 Billion107.91%
2015 -S$75.02 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-S$24.38 Million-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$0.33 Billion-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA